Indivior CEO granted 79,976 RSUs in stock award

Indivior Pharmaceuticals, Inc.’s Chief Executive Officer and director Joseph Ciaffoni reported receiving a grant of 79,976 shares of common stock in the form of restricted stock units at a price of $0 per share.

Rhea-AI Filing Summary

Indivior Pharmaceuticals, Inc.’s Chief Executive Officer and director Joseph Ciaffoni reported receiving a grant of 79,976 shares of common stock in the form of restricted stock units at a price of $0 per share. Following this equity award, he beneficially owns 135,976 common shares directly.

The RSUs vest in three equal annual installments starting on February 10, 2027, the first anniversary of the grant. Each unit represents the right to receive one share of common stock, contingent on his continued service with the company.

Insider Trade Summary

Grant/Award: 79,976 shares

Grant/Award 1 txn

Insider Ciaffoni Joseph

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	79,976	$0.00	$0.00

Holdings After Transaction: Common Stock — 135,976 shares (Direct)

Footnotes (1)

1. F1. Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, vesting in three equal annual installments beginning on February 10, 2027, the first anniversary of the grant, subject to the Reporting Person's continued service with the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Indivior (INDV) report for CEO Joseph Ciaffoni?

Indivior (INDV) reported that CEO Joseph Ciaffoni acquired 79,976 shares of common stock through a grant of restricted stock units at $0 per share. This equity award increased his directly owned beneficial stake to 135,976 common shares, aligning compensation with long-term company performance.

How many Indivior (INDV) shares does the CEO own after this Form 4 filing?

After this reported grant, Indivior (INDV) CEO Joseph Ciaffoni beneficially owns 135,976 shares of common stock directly. This total includes the 79,976 restricted stock units awarded, which convert into shares as they vest over the specified three-year schedule.

What are the terms of the restricted stock units granted at Indivior (INDV)?

The grant consists of 79,976 restricted stock units, each representing one share of Indivior (INDV) common stock. These RSUs vest in three equal annual installments beginning on February 10, 2027, contingent on the CEO’s continued service with the company through each vesting date.

When do the new RSUs for Indivior (INDV)’s CEO start vesting?

The restricted stock units granted to Indivior (INDV)’s CEO begin vesting on February 10, 2027. Vesting occurs in three equal annual installments from that date, meaning full vesting is spread over three years, subject to his ongoing service with the company.

Did the Indivior (INDV) CEO pay cash for the 79,976-share grant?

No cash was paid for this award; the 79,976 Indivior (INDV) shares were granted at a price of $0 per share as restricted stock units. This reflects a compensation-linked equity grant rather than an open-market purchase of the company’s stock.

Is the Indivior (INDV) CEO’s new equity grant based on RSUs or stock options?

The new equity award for Indivior (INDV)’s CEO is entirely in restricted stock units, not stock options. Each RSU provides a contingent right to receive one share of common stock as it vests over three years, aligning his incentives with shareholder outcomes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 04:02 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ciaffoni Joseph

(Last) (First) (Middle)

10710 MIDLOTHIAN TURNPIKE

SUITE 125

(Street)

NORTH CHESTERFIELD VA 23235

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Indivior Pharmaceuticals, Inc. [ INDV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		A		79,976(1)	A	$0	135,976	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, vesting in three equal annual installments beginning on February 10, 2027, the first anniversary of the grant, subject to the Reporting Person's continued service with the Issuer.

Remarks:

Exhibit 24 Power of Attorney

	/s/Alice Givens, Power of Attorney	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.